Abstract
The fluoroquinolones have been in clinical use for over 50 years for community- and hospital-associated infections, but widespread, often indiscriminate, use has fueled progressive antimicrobial global resistance. The older quinolones had limited gram-positive antibacterial activity and were not effective against methicillin-resistant staphylococci, thus rarely used in skin and soft tissue infections. Delafloxacin is a newly approved member of the class and is the only anionic (non-zwitterionic) fluoroquinolone. Its unique structure results in enhanced activity against gram-positive bacteria, including methicillin-resistant staphylococci, which is further enhanced by an acidic environment such as found in abscesses. Delafloxacin is available for intravenous and oral administration and is approved in several countries for skin and soft tissue infections. In this chapter the antimicrobial activity, pharmacokinetic/pharmacodynamics properties, clinical efficacy, and side effects are reviewed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mogle BT, Steele JM, Thomas SJ, Bohan KB, Kufel WD. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother. 2018;73:1439–51.
Scott LJ. Delafloxacin: a review in acute bacterial skin and skin structure infections. Drugs. 2020;80:1247–58.
Hoover R, Hunt T, Benedict M, et al. Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age. Clin Ther. 2016;38:39–52.
Hoover R, Hunt T, Benedict M, et al. Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers. Clin Ther. 2016;38:53–65.
Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003;47:3260–9.
Burak ES, Devito JA, Remy JM, et al. Delafloxacin chemical properties lead to increased potency against gram-positive pathogens, including quinolone-resistant pathogens. In: Proceedings of the 50th intersc conf antimicrob agents chemother; Boston, MA, USA, 20210. {Poster E-182}. Washington, DC: American Society for Microbiology.
Lemaire S, Tulkens PM, Bambbeke VF. Contrasting effects of acidic pH on the extracellular and intracelllular activities of the anti-gram-positive fluoroquinolones against Staphylococcus aureus. J Antimicrob Chemother. 2011;55:649–58.
Bauer J, Siala W, Tulkens PM, Van Bambeke F. A combined pharmacodynamics quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother. 2013;57:2726–37.
Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D, Jones RN. Delafloxacin in vitro broth microdilution and disk diffusion antimicrobial susceptibility breakpoint criteria and quality control ranges for an expanded-spectrum anionic fluoroquinolone. J Clin Microbiol. 2018;56:e00339–18.
Tulkens PM, Bamabeke F, Zinner SH. Profile of a novel fluoroquinolone—delafloxacin. Clin Infect Dis. 2019;68(S3):S213–22.
Brown Elliot BA, Wallace RJ. Comparison of in vitro susceptibility of delafloxacin with ciprofloxacin, moxifloxacin, and other comparator antimicrobials against isolates on nontuberculous mycobacteria. Antimicrob Agents Chemother. 2021;65(7):e0007921. https://doi.org/10.1128/AAC.00079-21.
Hermsen ED, Hovde LB, Konstantinides GN, et al. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens. Antimicrob Agents Chemother. 2005;49:1633–5.
Armer LS, Hoffrage JB, Keller EL, et al. In vitro bactericidal activities against gram-positive and gram-negative organisms. Antimicrob Agents Chemother. 2004;49:2771.
Soge OO, Salipante SJ, No D, et al. In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance. Antimicrob Agents Chemother. 2016;60:106–11.
Giordano PA, Pogue JM, Cammarata S. Analysis of pooled phase III efficacy data for delafloxacin in acute bacterial skin and skin structure infections. Clin Infect Dis. 2019;68(S3):S223–32.
Horcajada JP, Salata RA, Alvarez-Sala R, et al. A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia [DEFINE-CABP]. Open forum. Infect Dis. 2020;7:ofz514. https://doi.org/10.1093/ofid/ofz514.
Jorgensen SCJ, Mercuro NJ, Davis SL, Ryback MJ. Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Therapy. 2018;7:197–217.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Fong, I.W. (2023). A New Fluoroquinolone: Delafloxacin. In: New Antimicrobials: For the Present and the Future. Emerging Infectious Diseases of the 21st Century. Springer, Cham. https://doi.org/10.1007/978-3-031-26078-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-031-26078-0_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-26077-3
Online ISBN: 978-3-031-26078-0
eBook Packages: MedicineMedicine (R0)